Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients

Long acting somatostatin analogues could be used as an additive therapy in combination to antineoplastic agents in patients positive for somatostatin receptors. A dose of 30 mg improved survival only in LD SCLC patients.